Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma | Zendy

Jan C. Buckner | Zendy; Edward G. Shaw | Zendy; Stephanie L. Pugh | Zendy; Arnab Chakravarti | Zendy; Mark R. Gilbert | Zendy; Geoffrey R. Barger | Zendy; Stephen W. Coons | Zendy; Peter E. Ricci | Zendy; Dennis E. Bullard | Zendy; Paul D. Brown | Zendy; K. Stelzer | Zendy; David Brachman | Zendy; John H. Suh | Zendy; Christopher J. Schultz | Zendy; Jean-Paul Bahary | Zendy; Barbara J. Fisher | Zendy; Harold Kim | Zendy; Albert Murtha | Zendy; Erica H. Bell | Zendy; Minhee Won | Zendy; Minesh P. Mehta | Zendy; Walter J. Curran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

Author(s) -

Jan C. Buckner,

Edward G. Shaw,

Stephanie L. Pugh,

Arnab Chakravarti,

Mark R. Gilbert,

Geoffrey R. Barger,

Stephen W. Coons,

Peter E. Ricci,

Dennis E. Bullard,

Paul D. Brown,

K. Stelzer,

David Brachman,

John H. Suh,

Christopher J. Schultz,

Jean-Paul Bahary,

Barbara J. Fisher,

Harold Kim,

Albert Murtha,

Erica H. Bell,

Minhee Won,

Minesh P. Mehta,

Walter J. Curran

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1500925

Subject(s) - medicine , procarbazine , lomustine , vincristine , radiation therapy , oligodendroglioma , surgery , chemotherapy , glioma , astrocytoma , hazard ratio , cyclophosphamide , confidence interval , cancer research

Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration and premature death. Early results of this trial showed that treatment with procarbazine, lomustine (also called CCNU), and vincristine after radiation therapy at the time of initial diagnosis resulted in longer progression-free survival, but not overall survival, than radiation therapy alone. We now report the long-term results.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research